Pharmacovigilance in juvenile idiopathic arthritis patients (Pharmachild) treated with biologic agents and/or methotrexate. Consolidated baseline characteristics from Pharmachild and other national registries

Similar Items

• Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries
  od: Swart, Joost, i dr.
  Izdano: (2018)
• Nearly 20% of children are not correctly classified according to current ilar classification in a PRINTO dataset of more than 12,000 juvenile idiopathic arthritis patients
  od: Consolaro, Alessandro, i dr.
  Izdano: (2014)
• Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee
  od: Giancane, Gabriella, i dr.
  Izdano: (2020)
• The Lithuanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
  od: Rusoniene, Skirmante, i dr.
  Izdano: (2018)
• Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry
  od: Horneff, Gerd, i dr.
  Izdano: (2017)